This report describes unrelated umbilical cord blood transplantation for a 10-month-old infant boy with mucopolysaccharidosis IIB (Hunter syndrome), an Xlinked metabolic storage disorder due to deficiency of iduronate sulfatase. Two years after transplant ෂ55% normal plasma enzyme activity has been restored and abnormal urinary excretion of glycosaminoglycans has nearly completely resolved. The boy has exhibited normal growth and development after transplant. Nine months after transplant he developed severe autoimmune hemolytic anemia and required 14 months of corticosteroid treatment to prevent clinically significant anemia. Bone marrow transplantation for Hunter syndrome and post-transplant hemolytic anemia are reviewed. Bone Marrow Transplantation (2000) 25, 1093-1097.
a median of 21 years in type IIB. 8 Allogeneic BMT has been used to treat Hunter disease, but remains controversial since it often fails to reverse CNS impairment [9] [10] [11] and carries with it substantial early mortality and morbidity. Here, we report treatment of an infant with mucopolysaccharisosis type IIB with transplantation of unrelated umbilical cord blood cells and its complication by autoimmune hemolytic anemia.
Case report
The patient is the only child of a couple with a maternal family history of Hunter syndrome. The mother's brother was diagnosed with Hunter syndrome in 1979 at age 3 years when he exhibited the physical stigmata of the disorder. The diagnosis was corroborated by detection of large amounts of glycosaminoglycans in the urine. This uncle exhibited growth retardation; at age 20 years his weight was 40 kg and height 4 feet. He experienced multiple upper respiratory tract infections related to airway obstruction, hepatosplenomegaly, severe contractures with limitation of range of joints in all limbs, and deafness. He died at age 20 years due to cardiac dysfunction, the most common cause of death in type IIB mucopolysaccharidosis. He was above average in intelligence, attended a regular school until the 7th grade when physical disability caused his withdrawal, and had no neurological problems other than deafness.
Because of the family history the patient was screened for Hunter disease at age 1 month. He had profound deficiency of iduronate-2-sulfatase activity and substantially elevated urinary glycosaminoglycans (Table 1) . Mutational analysis demonstrated an A to G substitution in intron 6 at the 8th base upstream of exon 7 (1004-8AG). The mother, grandmother and two maternal aunts were carriers of the same mutation. At 4 months he was evaluated for allogeneic HSC transplant. His growth and development were normal, but he had mild hepatomegaly. Repeat laboratory evaluation confirmed absence of enzyme activity and abnormal excretion of urinary glycosaminoglycans (Table  1) . Echocardiography was normal. Neuropsychological evaluation using Bayley scales at age 9 months showed a mental age of 9 months and a motor age of 10 months. The transplant was marked by two episodes of gram-positive bacteremia, one episode of limited gastrointestinal bleeding while thrombocytopenic, and mucositis requiring total parenteral nutrition for several weeks. Two weeks after transplant he developed grade 3 skin GVHD involving Ͼ80% of his body (nonblistering rash) and also developed grade 2 gastrointestinal GVHD (2-7 diarrheal stools/day). Methylprednisolone 2 mg/kg was added with resolution of GVHD symptoms. He was tapered off corticosteroids by day 60. At day 131 he experienced substantial skin rash again and a biopsy was consistent with GVHD. He was treated for 2 months with corticosteroids and improved. He continued to receive tacrolimus.
His hepatomegaly resolved and he continued to grow and develop normally. RFLP analysis 8 months after BMT demonstrated his marrow was 100% donor in origin. Biochemical tests 2 years after transplant demonstrated serum iduronate-2-sulfatase levels 55% of the concurrent normal control. (The patient's activity was within the range of normal.) He exhibited normal urinary excretion of the glycosaminoglycans uronic acid and hexosamine N-sulfate, but qualitative electrophoresis of urine still demonstrated small amounts of dermatan sulfate, heparan sulfate and chondroitin sulfate ( Table 1) .
The post-BMT course was complicated at 9 months by severe hemolytic anemia (hemoglobin 6.3 g/dl, 36% reticulocytes, LDH 1607 IU/l, indirect bilirubin 0.9 mg/dl, direct bilirubin 0.1 mg/dl). Initially the patient had a normal platelet count but within 2 weeks developed thrombocytopenia (33 000/l). Leukopenia was never observed. Both direct and indirect antiglobulin (Coombs') tests were positive for IgG but negative for complement. This warm autoantibody was determined to have an anti-e specificity. Tests for anti-platelet and anti-nuclear antibodies were negative. He was treated with prednisone 2 mg/kg/day. Thrombocytopenia resolved within 4 weeks, and hemoglobin levels also rose (12 g/dl). Two months later he was weaned from prednisone, but one 1 month thereafter, following an upper respiratory tract infection, his hemolytic anemia worsened (8 g/dl). Reinstitution of prednisone was followed by normalization of hemoglobin levels. Three months later another attempt to wean the patient from steroids failed. Splenectomy was considered but not performed. The patient remained on prednisone and tacrolimus and remained stable, although he continued to have elevated reticulocyte counts and was Coombs' test positive. Seventeen months after transplant he was successfully weaned from tacrolimus without exacerbation of GVHD. Prednisone was slowly tapered over 6 months while blood counts remained stable. Twenty-six months post transplant he is off all immunosuppressant drugs and is growing and developing normally. His blood counts are normal (hemoglobin 12.7 g/dl, WBC 9400 cells/l, platelets 235 000/l, reticulocytes 0.4%). He continues to have a positive direct Coombs' test.
Discussion
Hematopoietic stem cell transplantation for Hunter syndrome is controversial because published series of BMT in Hunter variants with substantial CNS impairment have demonstrated little improvement in CNS functioning. [9] [10] [11] This result has been also seen in other metabolic storage diseases with substantial CNS components. 12 Moreover, lifelong prevention of cardiac dysfunction (the most common cause of death in type IIB 8 ) has yet to be proven, although there has been a report of reversal of cardiac valvular abnormalities as measured by echocardiography in a 14-year-old boy with type IIB Hunter syndrome who underwent BMT. 13 Some have argued that transplant may have a role in such disorders if it can be performed quite early in life 12 before irreversible organ damage occurs. In many cases this is not possible since the diagnosis is not made until early childhood after the disease has become clinically evident. In this case the decision to proceed with unrelated donor HSC transplant was based on several considerations. First, the diagnosis was made in the first few months of life before irreversible organ damage occurred. Second, while the mutations in Hunter syndrome are extremely heterogeneous and a strict genotype-phenotype correlation has not been established, 6 the family history indicated that CNS impairment was not a primary feature of the disease in this kindred. Moreover, the storage disease produced unacceptable quality of life and was ultimately lethal for the maternal uncle. Third, an unrelated umbilical cord blood unit with acceptable HLA-matching could be identified and procured within 3 months. Early experience with UCB transplantation for more common conditions (eg leukemia) has indicated that while fatal GVHD can occur, the incidence of grades 3 and 4 GVHD for a particular degree of mismatching may be less than that seen with unrelated donor marrow or peripheral blood stem cell transplantation.
14 Clinical results 2 years after transplant indicate that biochemical measures of the Hunter syndrome are being corrected. While BMT can correct the enzyme deficiency in marrow-derived cells but not other somatic cells, the enzymatic activity of these marrow-derived cells may be able to substantially reduce the total body burden of glycosaminoglycans either directly or indirectly by release of iduronate 2-sulfatase and subsequent uptake by other tissues through endocytosis. 10 The results in this patient are compatible with this hypothesis. One parameter of body burden of glycosaminoglycans is the quantity of glycosaminoglycans in urine, while the more sensitive 10 Clinically this patient has had regression of hepatomegaly. Follow-up over the next 10 years should indicate whether the transplant will prevent long-term organ dysfunction.
Nine months after transplant the patient developed severe hemolytic anemia. Alloimmune hemolysis was an unlikely explanation for the process since more than 7 months had transpired since the last transfusion of red cells or platelets. Moreover, the specificity of the responsible IgG was antie, and was not directed against either major or minor blood group antigens associated with blood group incompatibilities. Autoimmune hemolytic anemia and other autoimmune disorders have been reported after hematopoietic stem cell transplantation, 15 ,16 although they have not been extensively reported after umbilical cord blood transplantation. Autoantibodies have been observed in 8% of patients with chronic GVHD, 17 and autoimmune cytopenias do occur (although the manifestations are more commonly thrombocytopenia or neutropenia). 18 Hemolytic anemia is also associated with a variety of lymphocytic malignancies and immunodeficiency states. In these settings responses to corticosteroids are often incomplete and transient. The prognosis for complete remission of the hemolytic anemia in these conditions is poorer than in patients with idiopathic autoimmune hemolytic anemia, possibly because of the underlying disorders. 19, 20 This patient had a quick and satisfactory response to steroids, possibly portending a good prognosis. The significance of a very brief period of associated thrombocytopenia is unknown, especially since antiplatelet antibodies were never identified. Hemolytic anemia with immune thrombocytopenia (Evan's syndrome) has a poorer prognosis than hemolytic anemia. [20] [21] [22] In this patient the immunopathogenesis of the hemolytic anemia is unknown. It is conceivable that given the blood group incompatibility the patient (Rh−) may have some residual recipient B cells that react against the incompatible donor (Rh+) Rho proteins (although the IgG identified was not specific for the typical anti-D antigen which represents the most common antigen disparity in Rh incompatibility). RFLP analysis indicates 100% donor hematopoiesis, but does not exclude microchimerism. More likely is the possibility that the hemolytic anemia is truly autoimmune since the direct antiglobulin test demonstrated red cell bound IgG1 antibodies with anti-e specificity. Such warm autoantibodies are the most common type identified in autoimmune hemolytic anemia. The direct antiglobulin test did not identify red cell bound complement. However, several series reviewing warm (IgG) autoimmune hemolytic anemia have demonstrated that while both IgG and complement can be detected on red cells in half to two-thirds of cases, a sizable fraction (up to a third) may be associated with IgG only, or even complement alone. 23 This autoimmunity could be a manifestation of GHVD. Alternatively, the autoimmunity may be the product of immune dysregulation following transplant. 15 If so, with time and the absence of tacrolimus, normal immune homeostasis may be established and the hemolytic process may completely abate. Similarly to the Hunter syndrome this is a possibility that will only be established with time.
While the decision to proceed with an unrelated umbilical cord blood transplant for Hunter syndrome IIB can be justified, it is emotionally very difficult for both parents and caregivers. In this case the parents were fully informed of the very substantial risks of early death and substantial morbidity from transplant, but accepted them after concluding that the quality of life without transplant was unacceptable. A substantial possibility of long-term survival was considered to be better than a very high probability of reduced survival (median 21 years in Hunter IIB) with substantial disabilities. Other people of good will could reach another decision. Until gene therapy technology experiences substantial improvements, 24, 25 the increased availability of umbilical cord blood units for transplantation may increase the number of transplants performed for conditions other than cancer such as immunodeficiencies, metabolic storage diseases and hemoglobinopathies in which survival without transplant is expected to be a decade or more. 14 We believe it is imperative that in such situations the process of informed consent should be exceptionally thorough and in some circumstances may require ethics consultation. While many families of affected children are extremely well informed about the underlying genetic condition, they often have little or no understanding of the risks or intensity of BMT. It is critical that parents fully appreciate the probabilities of graft rejection, early death from infection, hemorrhage, regimen-related toxicity, and graft-versus-host disease. They must also understand that BMT will not reverse CNS damage. Our point of view is that BMT cannot be ethically justified in patients who have already experienced a substantial decline in CNS function.
